Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
ISIS-TTRRx
print preview
bookmark
share with colleague
General Information
Company
Isis Pharmaceuticals Inc.
Description
TTR antisense inhibitor
Molecular Target
Transthyretin (TTR)
Mechanism of Action
Antisense therapy
Latest Stage of Development
Phase II/III
Indication
Amyloidosis
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information